Do pneumococcal conjugate vaccines represent good value for money in a lower-middle income country? A cost-utility analysis in the Philippines

10.1371/journal.pone.0131156

Saved in:

Bibliographic Details
Main Authors:	Haasis M.A., Ceria J.A., Kulpeng W., Teerawattananon Y., Alejandria M.
Other Authors:	SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH
Format:	Article
Published:	Public Library of Science 2020
Subjects:	Pneumococcus conjugate vaccine 10 Pneumococcus vaccine unclassified drug 10-valent pneumococcal conjugate vaccine 13-valent pneumococcal vaccine vaccine Article cohort analysis cost effectiveness analysis cost utility analysis drug cost drug efficacy economic evaluation government health care access health care cost health care delivery herd immunity human Philippines pneumococcal infection preventive health service program sustainability quality adjusted life year statistical model adolescent adult aged child cost benefit analysis drug effects economics female financial management immunology income infant male Markov chain microbiology middle aged newborn Pneumonia, Pneumococcal preschool child Streptococcus pneumoniae vaccination Adolescent Adult Aged Child Child, Preschool Cost-Benefit Analysis Female Financing, Government Humans Immunization Programs Income Infant Infant, Newborn Male Markov Chains Middle Aged Pneumococcal Vaccines Vaccination Vaccines, Conjugate
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/165692
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

Similar Items